Latest On MERCK Kommanditgesellschaft auf Aktien (MKKGY):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2024-04-29 05:57 EST | Dividend | A dividend of $0.47 has been announced on Apr 4, 2024. It will be paid May 9, 2024 with an ex-dividend date of Apr 29, 2024. | Neutral |  |
| 2023-05-12 03:03 EST | News | Merck KGaA (MKGAF) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-11 12:59 EST | News | Merck KGaA 2023 Q1 - Results - Earnings Call Presentation | N/A | |
| 2023-05-02 05:56 EST | Dividend | A dividend of $0.47 has been announced on Mar 16, 2023. It will be paid May 11, 2023 with an ex-dividend date of May 2, 2023. | Neutral | |
| 2023-04-29 01:55 EST | News | Germany rebuffs report it is pursuing chemical export control to China | N/A | |
| 2023-04-27 12:25 EST | News | Germany may limit exporting of chemicals used for semiconductors to China | N/A | |
| 2023-04-18 17:20 EST | News | Merck KGaA: A German Free Cash Flow Machine | N/A | |
| 2023-04-12 10:16 EST | News | Merck KGaA stock falls after FDA pauses new patients on MS drug evobrutinib in trial | N/A | |
| 2023-03-27 23:18 EST | News | Pfizer and Merck KGaA end global collaboration for cancer therapy Bavencio | N/A | |
| 2023-03-03 00:20 EST | News | MERCK Kommanditgesellschaft auf Aktien (MKGAF) Q4 2022 Results - Earnings Call Transcript | N/A | |
| 2023-03-03 00:20 EST | News | MERCK Kommanditgesellschaft auf Aktien 2022 Q4 - Results - Earnings Call Presentation | N/A | |
| 2023-01-04 12:37 EST | News | Trim Big Pharma For Merck KgaA | N/A | |
| 2022-12-23 16:48 EST | News | Mersana Therapeutics in deal with Merck KGaA for antibody-drug conjugates | N/A | |
| 2022-12-23 00:14 EST | News | Mersana Therapeutics in deal with Merck KGaA for antibody drug conjugates | N/A | |
| 2022-11-29 16:05 EST | News | Pfizer, Merck KGaA join Immutep in Phase 1 trial for kidney cancer therapy | N/A | |
| 2022-11-16 20:51 EST | News | Merck KGaA to invest $286M at Maryland site to boost drug safety testing capacity | N/A | |
| 2022-11-11 02:10 EST | News | MERCK Kommanditgesellschaft auf Aktien (MKGAF) CEO Belen Garijo on Q3 2022 Results - Earnings Call Transcript | N/A | |
| 2022-11-10 08:34 EST | News | Merck KGaA Q3 sales grow on back of Life Science business, confirms FY22 outlook | N/A | |
| 2022-10-26 08:54 EST | News | Merck KGaA multiple sclerosis drug evobrutinib shows benefit across 3 years in trial | N/A | |
| 2022-10-19 17:28 EST | News | Merck KGaA to be probed in France over thyroid drug levothyrox | N/A | |
| 2022-10-11 22:50 EST | News | PDS Biotech stock soars 14% as PDS0101 shows promise vs HPV-positive cancers in interim trial data | N/A | |
| 2022-10-07 08:58 EST | News | Merck KGaA mulls 'larger-scale acquisitions' from 2023 onwards; focus on 'Big 3' for sales growth | N/A | |
| 2022-09-21 17:32 EST | News | Merck KGaA in licensing deal with Nerviano Medical for PARP inhibitor | N/A | |
| 2022-09-08 20:33 EST | News | MilliporeSigma, subsidiary of Merck KGaA to invest €130M for strengthening manufacturing capabilities in France | N/A | |
| 2022-08-31 21:55 EST | News | Guardant Health expands collaboration with Merck KGaA on precision oncology therapies | N/A | |
| 2022-08-09 13:04 EST | News | MERCK Kommanditgesellschaft auf Aktien (MKGAF) CEO Belen Garijo on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-08-04 19:41 EST | News | Merck KGaA Q2 sales grow on all-round show, raises FY22 outlook | N/A | |
| 2022-08-04 19:41 EST | News | MERCK Kommanditgesellschaft auf Aktien 2022 Q2 - Results - Earnings Call Presentation | N/A | |
| 2022-06-01 23:43 EST | News | Merck KGaA, South Korea's Standigm team up for AI-based drug discovery research | N/A | |
| 2022-05-23 07:31 EST | News | Merck KGaA to invest ~€440M to boost manufacturing capacity in Ireland | N/A | |
| 2022-05-14 06:25 EST | News | Merck KGaA (MKGAF) CEO Belén Garijo on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-13 03:31 EST | News | MERCK Kommanditgesellschaft auf Aktien Non-GAAP EPS of €2.41, revenue of €5.2B; updates FY22 guidance | N/A | |
| 2022-05-13 03:31 EST | News | MERCK Kommanditgesellschaft auf Aktien 2022 Q1 - Results - Earnings Call Presentation | N/A | |
| 2022-05-12 07:32 EST | News | Merck KGaA Q1 sales rises on the back of Life Science business; confirms FY22 outlook | N/A | |
| 2022-04-25 05:56 EST | Dividend | A dividend of $0.41 has been announced on Mar 17, 2022. It will be paid May 4, 2022 with an ex-dividend date of Apr 25, 2022. | Neutral | |
| 2022-04-08 07:44 EST | News | Pfizer-Merck KGaA's Bavencio gets UK's NICE backing for use in bladder cancer | N/A | |
| 2022-03-08 05:06 EST | News | Merck KGaA weighs sale of pigments business valued at over 1 billion dollars | N/A | |
| 2022-03-03 20:59 EST | News | MERCK Kommanditgesellschaft auf Aktien 2021 Q4 - Results - Earnings Call Presentation | N/A | |
| 2022-03-03 20:59 EST | News | MERCK Kommanditgesellschaft auf Aktien (MKGAF) CEO Belén Garijo on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-02-19 03:13 EST | News | Merck KGaA Bavencio shows survival benefit in bladder cancer in long term data | N/A | |
| 2022-02-08 09:08 EST | News | Merck KGaA integrates CDMO, Contract Testing in new Life Science Services organization | N/A | |
| 2021-12-30 21:38 EST | News | German Merck unit awarded ~$137M DoD contract for material used in rapid COVID tests | N/A | |
| 2021-12-30 04:37 EST | News | MilliporeSigma wins $136.7M U.S. government contract | N/A | |
| 2021-12-07 21:33 EST | News | Palantir, Merck partner to tackle chip shortage | N/A | |
| 2021-11-24 09:21 EST | News | Merck KGaA partner granted FDA Fast Teck Designation for cancer drug | N/A | |
| 2021-11-11 16:45 EST | News | MERCK Kommanditgesellschaft auf Aktien (MKGAF) CEO Belén Garijo on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-10-01 02:47 EST | News | GlaxoSmithKline, Merck KGaA end partnership for cancer therapy | N/A | |
| 2021-09-09 15:36 EST | News | Merck KGaA to leverage “Big 3” in pursuit of €25 billion group revenue in 2025 | N/A | |
| 2021-08-23 18:52 EST | News | Merck KGaA halts mid-stage trial for bintrafusp alfa in biliary tract cancer | N/A | |
| 2021-08-08 04:09 EST | News | MERCK Kommanditgesellschaft auf Aktien (MKGAF) CEO Belen Garijo on Q2 2021 Results - Earnings Call Transcript | N/A | |
About MERCK Kommanditgesellschaft auf Aktien (MKKGY):
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer or multiple sclerosis, infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as carcinoma of the head and neck; prescription drugs for allergen immunotherapy; and fertility treatments. The company also provides life science products and services for the research and applied laboratory applications, as well as for formulating, purifying, manufacturing, and quality-assuring drug therapies of chemical and biological origin; and specialty chemicals, such as liquid crystals and OLED materials for use in displays, materials for integrated circuits, effect pigments for coatings and color cosmetics, as well as functional materials for energy solutions. It has strategic alliances with Pfizer Inc. and GlaxoSmithKline plc; agreement with Intrexon Corporation and Avillion LLP; collaboration with F-star Delta Ltd.; an agreement IAVI and Serum Institute of India Pvt. Ltd. to develop SARS-CoV-2 neutralizing monoclonal antibodies; and collaboration with Iktos for new drug design. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.
General
- Name MERCK Kommanditgesellschaft auf Aktien
- Symbol MKKGY
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 58,127
- Last Split Factor1666:1000
- Last Split Date2017-08-15
- Fiscal Year EndDecember
- Web URLhttp://www.merckgroup.com
Valuation
- Trailing PE 31.86
- Forward PE 19.19
- Price/Sales (Trailing 12 Mt.) 3.35
- Price/Book (Most Recent Quarter) 3.46
- Enterprise Value Revenue 4.71
- Enterprise Value EBITDA 16.67
Financials
- Most Recent Quarter 2020-12-31
- Profit Margin 11%
- Return on Assets 5%
- Return on Equity 11%
- Earnings Per Share $1.04
- Revenue Per Share $0
- Gross Profit 10.75 billion
- Quarterly Earnings Growth 5%
Highlights
- Market Capitalization 71.43 billion
- PEG Ratio 3.08
- Analyst Target Price $28
- Book Value Per Share $8.17
Share Statistics
- Shares Outstanding 2.17 billion
- Shares Float 646.2 million
- % Held by Insiders <1%
- % Held by Institutions 0.18%
Technicals
- Beta 0.44
- 52 Week High $36.5
- 52 Week Low $17.25
- 50 Day Moving Average 33.07
- 200 Day Moving Average 31.92
Dividends
- Forward Annual Dividend Rate $0.29
- Forward Annual Dividend Yield 0.91%
- Payout Ratio 6%
- Dividend Date 2020-06-10
- ExDividend Date 2020-06-01
- Dividend Per Share $1.46
- Dividend Yield 0%
MERCK Kommanditgesellschaft auf Aktien (MKKGY) Dividend Calendar:
MKKGY's last dividend payment was made to shareholders on June 10, 2020.
MERCK Kommanditgesellschaft auf Aktien pays out 6% of its earnings out as a dividend.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|---|---|---|---|
| 2024-04-29 | 2024-05-09 | 2024-04-30 | 2024-04-04 | $0.47 |
| 2023-05-02 | 2023-05-11 | 2023-05-03 | 2023-03-16 | $0.47 |
| 2022-04-25 | 2022-05-04 | 2022-04-26 | 2022-03-17 | $0.41 |
| 2021-04-26 | 2021-05-05 | 2021-04-27 | 2021-03-19 | $0.33 |
| 2020-06-01 | 2020-06-10 | 2020-06-02 | 2020-05-05 | $0.28 |
| 2019-04-29 | 2019-05-09 | 2019-04-30 | 2019-03-26 | $0.28 |
| 2018-05-01 | 2018-05-10 | 2018-05-02 | $0.3 | |
| 2017-05-01 | 2017-05-19 | 2017-05-03 | 2017-04-10 | $0.44 |
| 2016-04-27 | 2016-05-17 | 2016-04-29 | 2016-02-18 | $0.4 |
| 2015-04-15 | 2015-05-05 | 2015-04-17 | 2015-04-03 | $0.36 |
MERCK Kommanditgesellschaft auf Aktien (MKKGY) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-03-04 | $N/A | $0.24 | ||
| 2020-09-30 | 2020-12-31 | $N/A | $1.22 | ||
| 2020-06-30 | 2020-09-30 | $N/A | $2.17 | ||
| 2020-03-31 | 2020-06-30 | $4.37 billion | $0.75 | ||
| 2019-12-31 | 2020-03-31 | $4.91 billion | $1.16 | ||
| 2019-09-30 | 2019-12-31 | $4.42 billion | $0.86 | ||
| 2019-06-30 | 2019-09-30 | $4.51 billion | $0.86 | ||
| 2019-03-31 | 2019-06-30 | $4.2 billion | $1.10 | ||
| 2018-12-31 | 2019-03-31 | $4.46 billion | $0.51 | ||
| 2018-09-30 | 2018-12-31 | $4.34 billion | $0.47 | ||
| 2018-06-30 | 2018-09-30 | $4.32 billion | $0.85 | ||
| 2018-03-31 | 2018-06-30 | $4.29 billion | $0.65 | ||
| 2017-12-31 | 2018-03-31 | $4.62 billion | $0.94 | ||
| 2017-09-30 | 2017-12-31 | $4.37 billion | $2.84 | ||
| 2017-06-30 | 2017-09-30 | $4.45 billion | $1.67 | ||
| 2017-03-31 | 2017-06-30 | $3.86 billion | $1.08 | ||
| 2016-12-31 | 2017-03-31 | $3.83 billion | $1.20 | ||
| 2016-09-30 | 2016-12-31 | $0.65 | |||
| 2016-06-30 | 2016-09-30 | $1.18 | |||
| 2016-03-31 | 2016-06-30 | $0.80 | |||
| 2015-12-31 | 2016-03-31 | $1.55 | |||
| 2015-09-30 | 2015-11-12 | $0.19 | |||
| 2015-06-30 | 2015-09-30 | $0.94 | |||
| 2015-03-31 | 2015-06-30 | $0.88 | |||
| 2014-12-31 | 2015-03-31 | $0.70 | |||
| 2014-09-30 | 2014-12-31 | $0.78 | |||
| 2014-06-30 | 2014-09-30 | $0.72 | |||
| 2014-03-31 | 2014-06-30 | $0.96 | |||
| 2013-12-31 | 2014-03-31 | $1.03 | |||
| 2013-09-30 | 2013-12-31 | $0.89 | |||
| 2013-06-30 | 2013-09-30 | $1.06 | |||
| 2013-03-31 | 2013-06-30 | $0.95 | |||
| 2012-12-31 | 2013-03-31 | $0.78 | |||
| 2012-09-30 | 2012-12-31 | $0.82 | |||
| 2012-06-30 | 2012-09-30 | $0.55 | |||
| 2012-03-31 | 2012-06-30 | -$0.18 | |||
| 2011-12-31 | 2012-03-31 | $0.53 | |||
| 2011-09-30 | 2011-12-31 | $0.40 | |||
| 2011-06-30 | 2011-09-30 | $0.69 | |||
| 2011-03-31 | 2011-06-30 | -$0.30 | |||
| 2010-12-31 | 2011-03-31 | $1.10 | |||
| 2010-09-30 | 2010-12-31 | $0.14 | |||
| 2010-06-30 | 2010-07-29 | $0.11 | |||
| 2010-03-31 | 2010-04-28 | $0.12 | |||
| 2009-12-31 | 2010-02-23 | $0.04 | |||
| 2009-09-30 | 2009-10-26 | $0.10 | |||
| 2009-06-30 | 2009-07-24 | $0.07 | |||
| 2009-03-31 | 2009-04-27 | $0.03 | |||
| 2008-12-31 | 2009-02-18 | -$0.17 | |||
| 2008-09-30 | 2008-10-27 | $0.14 | |||
| 2008-06-30 | 2008-07-23 | $0.15 | |||
| 2008-03-31 | 2008-04-23 | $0.17 |
MERCK Kommanditgesellschaft auf Aktien (MKKGY) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
MERCK Kommanditgesellschaft auf Aktien (MKKGY) Chart:
MERCK Kommanditgesellschaft auf Aktien (MKKGY) News:
Below you will find a list of latest news for MERCK Kommanditgesellschaft auf Aktien (MKKGY) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
MERCK Kommanditgesellschaft auf Aktien (MKKGY) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
MERCK Kommanditgesellschaft auf Aktien (MKKGY) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|